Jump to content
Paul Edwards

Data from a Phase II trial of ARN-509 (apalutamide)

Recommended Posts

Paul Edwards

"It is clear from these data that apalutamide has activity in the treatment of men with nmCRPC. This is not a surprise. However, the degree of promise for apalutamide based on these data (compared to other drugs already available on the market) is much harder to evaluate. Would treatment of this set of patients with either enzalutamide or abiraterone acetate have shown similar outcomes? We really don’t know."

 

Click on this link to read an article in the New Prostate Cancer Infolink about a recent Phase II trial.

 

 

Share this post


Link to post
Share on other sites

×
×
  • Create New...